Funded Tech Companies
Hemispherian
Researching who backed Hemispherian? Meneldor, Kistefos AS and Kvantia AS joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
Hemispherian
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Gaustadalléen 21
Oslo, 0349
Norway
Oslo, 0349
Norway
Phone
Website
Email Address
Company Background Information
Overview
Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers. The Company's lead compound is currently in late stage preclinical development for glioblastoma multiforme, a deadly cancer of the central nervous system.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
11/24/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zeno Albisser
Chief Operating Officer
Terezia Prikrylova
Chief Scientific Officer
Adam Robertson
Company Investors
- Meneldor
- Kistefos AS
- Kvantia AS
- Private Investors (Steven Powell)
- European Innovation Council Fund
- Norwegian
- Investinor
Browse more funded tech companies:
Share this article
About Our Venture Capital Transactions Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs